Coeptis Therapeutics Inc.: directors' dealings · United States · SEC (Form 4)

About Coeptis Therapeutics Inc.

Coeptis Therapeutics Inc. is a U.S.-listed biopharmaceutical company quoted on the NASDAQ market in the United States, with headquarters in Wexford, Pennsylvania. For French-speaking investors looking at the stock from a fundamental angle, Coeptis should be viewed as a small-cap biotech in strategic transition: it combines cell-therapy development with technology-oriented assets and a portfolio built around licensing and platform expansion rather than a single flagship drug. The company’s historical focus has been oncology, particularly hematologic malignancies and other high-unmet-need cancer settings. Its core story centers on cell-therapy platforms designed to improve the performance and durability of immune-based treatments. Two names matter most in the investment narrative: GEAR, short for Gene Edited Antibody Resistant, and the SNAP-CAR / NK programs. In practical terms, these platforms are intended to engineer immune cells so they can better attack tumors while potentially overcoming resistance mechanisms that limit current therapies. Coeptis has also referenced broader therapeutic opportunities in autoimmune and infectious diseases, which suggests a platform strategy with multiple possible paths to value creation. From a business-model perspective, Coeptis is trying to build intellectual-property leverage through licensing, subsidiary formation, and asset development partnerships. That is important because companies at this stage rarely have a mature commercial revenue base; instead, valuation is driven by pipeline progress, milestone execution, and strategic transactions. The company’s recent communications indicate that it is actively broadening and reorganizing its asset base, including the 2025 announcement that it secured worldwide development and commercialization rights to the next-generation GEAR cell-therapy platform. It also disclosed a broader transformation plan and a proposed merger transaction with Z Squared, with related SEC filings and Nasdaq-related updates in 2025 and early 2026. In competitive terms, Coeptis operates in a crowded and capital-intensive field dominated by better financed large pharmaceutical groups and a long list of clinical-stage cell-therapy developers. Its differentiators are platform flexibility, the possibility of multiple indications, and the optionality created by licensing and corporate restructuring. At the same time, investors should recognize the usual biotech risks: regulatory uncertainty, clinical development risk, dependency on financing, and potential dilution. Overall, Coeptis Therapeutics is best described as a speculative NASDAQ-listed United States biotech with a platform-driven oncology thesis, meaningful intellectual-property ambitions, and a recent corporate transformation that may reshape the investment case over time.